CLBT · Cellebrite DI
AI read · Neutral
The AI's read
Cellebrite missed Q2 revenue expectations, lowered full-year ARR guidance, and flagged delays closing large federal and European deals. Management also put a new CEO in place and stressed AI/product expansion as the fix. The market already hammered the stock about 32%, so a big chunk of the downside looks priced and upside is asymmetric right now. ARR still grew 21% to $508M, so the core business is growing even if execution lagged. We lean neutral: the news is negative but the share move removed most immediate pain, leaving execution and large-deal timing as the real catalysts from here. Watch whether sales can convert Insights customers and whether federal procurement delays clear up over the next quarters.